A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Cedazuridine/decitabine (Primary) ; Decitabine
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 08 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 06 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.